The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
Open accessAbstract
The role of dopamine agonist treatment in corticotroph pituitary tumors is controversial. The aim of this study was to evaluate D(2) receptor expression in 20 corticotroph pituitary tumors and to correlate it to the in vitro effect of dopamine agonists on ACTH secretion and the in vivo effect of short-term cabergoline treatment on cortisol secretion. D(2) expression was evaluated by receptor-ligand binding, immunohistochemistry, and RT-PCR. A 50% or more decrease in daily urinary cortisol levels was considered a significant clinical response. At receptor-ligand binding, specific binding of [(125)I]epidepride was found in 80% of cases. At immunohistochemistry, specific D(2) immunostaining was found in 75% of cases. D(2) expression was found in 83.3% of cases (D(2long) in 40%, D(2short) in 20%, and both in 40%) by RT-PCR. Significant in vitro inhibition of ACTH secretion was found in 100% of D(2)-positive cases, but not in 100% of D(2)-negative cases by either bromocriptine or cabergoline. A significant in vivo inhibition of cortisol secretion after 3-month cabergoline treatment was found in 60%, although a normalization of cortisol secretion was found in 40% of cases. All cabergoline-responsive cases were associated with D(2) expression, whereas all noncabergoline-responsive cases but one were not associated with D(2) expression. In conclusion, functional D(2) receptors were expressed in approximately 80% of corticotroph pituitary tumors. The effectiveness of cabergoline in normalizing cortisol secretion in 40% of cases supports its therapeutic use in the management of Cushing's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Dopamine: A Prolactin-Inhibiting Hormone*
BEN-JONATHAN, N. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-4-564 · Cited by 733
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Alternative splicing directs the expression of two D2 dopamine receptor isoforms
Giros, B., Sokoloff, P., Martres, M.-P., Riou, J.-F., Emorine, L. J., & Schwartz, J.-C. (1989) · Nature · doi:10.1038/342923a0 · Cited by 685
Molecular Diversity of the Dopamine Receptors
Civelli, O., Bunzow, J. R., & Grandy, D. K. (1993) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.001433 · Cited by 623
Orth, D. N. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321207 · Cited by 576
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Colao, A. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2664 · Cited by 450
Self-citationCaron, M. G., Beaulieu, M., Raymond, V., Gagné, B., Drouin, J., Lefkowitz, R. J., & Labrie, F. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38065-1 · Cited by 383
Regulation of prolactin secretion at the level of the lactotroph
Lamberts, S. W., & Macleod, R. M. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.279 · Cited by 353
Self-citationBochicchio, D. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.11.3114 · Cited by 344
Diagnosis and Management of Cushing’s Syndrome: Results of an Italian Multicentre Study 1
Invitti, C., Giraldi, F. P., De Martin, M., & Cavagnini, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5465 · Cited by 336
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationDopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas
DE CAMILLI, P., MACCONI, D., & SPADA, A. (1979) · Nature · doi:10.1038/278252a0 · Cited by 275
Resistance to Bromocriptine in Prolactinomas
PELLEGRINI, I., RASOLONJANAHARY, R., GUNZ, G., BERTRAND, P., DELIVET, S., JEDYNAK, C. P., KORDON, C., PEILLON, F., JAQUET, P., & ENJALBERT, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-500 · Cited by 267
Growth-hormone and prolactin excess
Colao, A., & Lombardi, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03356-x · Cited by 243
Self-citationCurrent Treatment Guidelines for Acromegaly1
Melmed, S., Jackson, I., Kleinberg, D., & Klibanski, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.4995 · Cited by 210
The Medical Treatment of Cushing's Syndrome
MILLER, J. W., & CRAPO, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-443 · Cited by 202
Transsphenoidal Surgery for Cushing's Disease
Fahlbusch, R., Buchfelder, M., & Müller, O. A. (1986) · Journal of the Royal Society of Medicine · doi:10.1177/014107688607900504 · Cited by 184
Management of Pituitary Tumors
Shimon, I., & Melmed, S. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-6-199809150-00009 · Cited by 165
Colao, A., Faggiano, A., Pivonello, R., Giraldi, F. P., Cavagnini, F., & Lombardi, G. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440499 · Cited by 158
Self-citationMUNEMURA, M., COTE, T. E., Tsuruta, K., Eskay, R. L., Kebabian, J. W., & Long, R. E. (1980) · Endocrinology · doi:10.1210/endo-107-6-1676 · Cited by 155
Pivonello, R., Matrone, C., Filippella, M., Cavallo, L. M., Somma, C. D., Cappabianca, P., Colao, A., Annunziato, L., & Lombardi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030859 · Cited by 152
Self-citationDopamine receptor agonists for treating prolactinomas
Colao, A., Somma, C. D., Lombardi, G., Pivonello, R., & Sarno, A. D. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.787 · Cited by 141
Self-citationLamberts, S. W. J., Klijn, J. G. M., Quijada, M. D., TIMMERMANS, H. A. T., UITTERLINDEN, P., de Jong, F. H., & Birkenhäger, J. C. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-2-307 · Cited by 128
Self-citationThe Case for Initial Surgical Removal of Certain Prolactinomas
Molitch, M. E., Thorner, M. O., Wilson, C., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.4.3845 · Cited by 125
Dopamine D2 Receptor Gene Expression in Human Adenohypophysial Adenomas
Ştefăneanu, L., Kovács, K., Horváth, É., Buchfelder, M., Fahlbusch, R., & Lancranjan, I. (2001) · Endocrine · doi:10.1385/endo:14:3:329 · Cited by 97
de Herder, W. W., Uitterlinden, P., Pieterman, H., Tanghe, H. L. J., Kwekkeboom, D. J., Pols, H. A. P., Singh, R. B., Berge, J., & Lamberts, S. W. J. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02448.x · Cited by 87
Self-citationDopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs.
Stack, J., & Surprenant, A. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018655 · Cited by 87
Renner, U., Arzberger, T., Pagotto, U., Leimgruber, S., Uhl, E., Müller, A., Lange, M., Weindl, A., & Stalla, G. K. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4685 · Cited by 77
Cronin, M. J., Cheung, C. Y., Wilson, C. B., Jaffe, R. B., & Weiner, R. I. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-2-387 · Cited by 73
Colao, A. A. L., Annunziato, L., & Lombardi, G. (1998) · Annals of Medicine · doi:10.3109/07853899809002486 · Cited by 73
Self-citationMemo, M., Castelletti, L., Missale, C., Valerio, A., Carruba, M. O., & Spano, P. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb13075.x · Cited by 68
Dopaminergic Receptors in Human Prolactin-Secreting Adenomas: A Quantitative Study*
BRESSION, D., Brandi, A., Martres, M., NOUSBAUM, A., Cesselin, F., Racadot, J., & Peillon, F. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-5-1037 · Cited by 66
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline
Pivonello, R., Faggiano, A., Salle, F. D., Filippella, M., Lombardi, G., & Colao, A. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343660 · Cited by 66
Self-citationACTH silent adenoma shrinking under cabergoline
Pétrossians, P., Ronci, N., Socin, H. V., Kalife, A., Stevenaert, A., Bloch, B., Tabarin, A., & Beckers, A. M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440051 · Cited by 47
Is there a role for somatostatin and its analogs in Cushing's syndrome?
de Herder, W. W., & Lamberts, S. W. J. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90091-8 · Cited by 44
Self-citationFailure of long-term therapy with sodium valproate in Cushing’s disease
Colao, A., Pivonello, R., Tripodi, F., Orio, F., Ferone, D., Cerbone, G., Somma, C. D., Merola, B., & Lombardi, G. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03347989 · Cited by 35
Self-citationEffect of injectable bromocriptine in patients with Cushing's disease
Invitti, C., Martin, M., Danesi, L., & Cavagnini, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211361 · Cited by 23
Cushing’s syndrome: drug targets and therapeutic options
Páez-Pereda, M., ARZT, E. S., & Stalla, G. K. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.10.1537 · Cited by 6
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationSomatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Metadata
- Authors
- Pivonello, R., Ferone, D., de Herder, W. W., Kros, J. M., Del Basso De Caro, M. L., Arvigo, M., Annunziato, L., Lombardi, G., Colao, A., Hofland, L. J., & Lamberts, S. W. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-05
- Volume
- 89
- Issue
- 5
- Pages
- 2452-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2170825600
- Cited by
- 271
- References
- 41
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.